Form 4: Sarepta Therapeutics Executive Bilal Arif Reports Stock Transactions
SEC Form 4 Filing
Bilal Arif, Chief Tech Ops Officer at Sarepta Therapeutics, reports the vesting of performance stock units and subsequent stock sales to cover tax obligations.
Summary
- Bilal Arif, Chief Tech Ops Officer of Sarepta Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On March 6, 2025, 17,500 shares vested under a performance stock unit (PSU) award granted on March 6, 2023.
- Following the vesting, Arif directly owns 33,782 shares of common stock.
- On March 7, 2025, 508 shares were sold at $103.7 to cover tax obligations related to restricted stock units vesting.
- An additional 8,527 shares were sold at $103.7 to cover tax obligations related to the vesting of the PSUs.
- After these transactions, Arif directly owns 24,747 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, which carries a neutral sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry.
Key Dates
| Date | Description |
|---|---|
| 03/06/2023 | Date of grant for the performance stock unit (PSU) award and restricted stock units. |
| 03/06/2025 | Date of vesting for 17,500 shares under the PSU award. |
| 03/07/2025 | Date of stock sales to satisfy tax withholding obligations. |
| 03/10/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.